Merck Knew of Vioxx Dangers, Report Charges

November 1, 2004
Internal Merck & Co. e-mails and documents show the company knew for years that its popular pain reliever Vioxx posed serious risks of heart attack and stroke, The Wall Street Journal reported.

Related Stories • Pfizer Pays Record $2.3 Billion Settlement Over Illegal Marketing Charges • Court Snuffs Vioxx Suit • Pfizer Pays $894 Million to Settle NSAID Claims • Researchers Claim Vioxx Safety Study Was Actually Marketing Plan • First Vioxx Judgment Overturned On Appeal • Merck Agrees to Pay $58 Million to Settle Vioxx Claims • Researchers Claim Merck Cooked Vioxx Data • Common Pain Relievers May Boost Muscle Mass • More Painkillers Can Cause More Pain • Merck Caves, Agrees To $4.85 Billion Vioxx Settlement • New York Sues Vioxx Maker over Drug’s Risks • Merck Wins Vioxx Case In Illinois • Judge Rules Out Vioxx "Super" Class Action • FDA Critic Blasts Merck's Vioxx Replacement • Merck Loses New Orleans Vioxx Case • Merck Wins Latest Vioxx Suit • Vioxx Study Authors Backtrack On Claim • Older Painkillers May Increase Heart Attack Risk • More about Vioxx --- Other NSAIDs • Bextra • Celebrex • Dangers of Other Vioxx-Type Drugs • Vioxx Alternatives • Aleve Ingredient Seen as Health Risk

When it pulled Vioxx off the market in September, Merck said it was "putting patient safety first" but the Journal says company officials had fought for years to protect the highly profitable drug and to keep news of the health risks quiet.

Vioxx was a big moneymaker for Merck, generating about $2.5 billion in yearly sales.

In early 2000, Merck research chief Edward Scolnick e-mailed Merck colleagues that the health risks "are clearly there." But the company continued to publicly reject any link between Vioxx and increased health risks.

Older and cheaper pain relievers such as aspirin and naproxen, known commercially as Aleve, block the COX-1 and COX-2 enzymes that are involved in inflammation and pain. Blocking COX-1 enzymes can upset the stomach but research indicates it may also help prevent blood clots, the leading cause of heart attacks and strokes.

Vioxx blocks only the COX-2 enzyme, thus providing powerful pain relief with no stomach upset. But clinical tests have indicated that it also fails to protect against blood clots and may even cause additional clots to form.

As far back as 1997, the Journal says Merck executives and scientists were discussing the risk. One said flatly that unless patients taking Vioxx also took aspirin, "you will get more thrombotic events," meaning blood clots. But adding aspirin would increase the risk of stomach irritation, leading to what another Merck official called "a no-win situation," the Journal said.

Merck responded that the comments were taken "out of context" and denied that it had purposely endangered its customers. In a statement, Merck said it had acted "responsibly and appropriately" in developing and marketing Vioxx.

Merck shares fell as much as 7 percent to their lowest level in more than eight years after the report.

Merck withdrew the drug September 30 after a study showed that prolonged usage could double the risk of heart attack and stroke in patients who took it for 18 months. That left about 1.3 million Americans looking for a substitute.

Researchers say the number of patients who have had heart attacks or strokes as a result of taking Vioxx could range from 30,000 to 100,000.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.

Back to the top |

Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2009 ConsumerAffairs.com Inc.  All Rights Reserved.    The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission.